APTX Aptinyx Inc.

3.84
-0.07  -2%
Previous Close 3.92
Open 3.93
52 Week Low 1.6
52 Week High 5.28
Market Cap $175,317,385
Shares 45,655,569
Float 26,298,526
Enterprise Value $57,721,552
Volume 191,553
Av. Daily Volume 389,348
Stock charts supplied by TradingView

Upcoming Catalysts

Drug Stage Catalyst Date
NYX-783
Post-traumatic stress disorder (PTSD)
Phase 2
Phase 2
Premium membership is required to view catalyst dates, analyst ratings, earnings dates and cash burn data. Click here to unlock and sign up to a 14-day FREE TRIAL.

Drug Pipeline

Drug Stage Notes
NYX-2925
Neuropathic Pain Associated with Diabetic Peripheral Neuropathy
Phase 2
Phase 2
Phase 2 enrollment to recommence late-2020/early-2021.
NYX-2925
Fibromyalgia
Phase 2
Phase 2
Phase 2 enrollment to recommence September 2020.
NYX-458
Parkinson’s Disease Cognitive Impairment (healthy volunteers)
Phase 2
Phase 2
Phase 2 enrolment has been suspended due to COVID-19.

Latest News

  1. Completed enrollment in Phase 2 exploratory study of NYX-783 in PTSD; data readout expected in 4Q 2020

    Recommencement of Phase 2 studies of NYX-2925 in chronic pain expected soon

    Conference call today at 5:00 p.m. ET

    Aptinyx Inc. (NASDAQ:APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today reported financial results for the second quarter of 2020 and highlighted recent progress across the company's clinical-stage pipeline of novel NMDA receptor modulators.

    "Despite the continuing COVID-19 health emergency, we have made important progress in advancing our pipeline of clinical-stage product candidates over the past few months," said Norbert…

    Completed enrollment in Phase 2 exploratory study of NYX-783 in PTSD; data readout expected in 4Q 2020

    Recommencement of Phase 2 studies of NYX-2925 in chronic pain expected soon

    Conference call today at 5:00 p.m. ET

    Aptinyx Inc. (NASDAQ:APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today reported financial results for the second quarter of 2020 and highlighted recent progress across the company's clinical-stage pipeline of novel NMDA receptor modulators.

    "Despite the continuing COVID-19 health emergency, we have made important progress in advancing our pipeline of clinical-stage product candidates over the past few months," said Norbert Riedel, Ph.D., president and chief executive officer of Aptinyx. "The recent completion of enrollment in our Phase 2 exploratory study of NYX-783 in patients with PTSD underscores this progress, as well as the ability of our team to operate in this new, highly complex environment. We are also pleased to announce that we will resume our studies of NYX-2925 in chronic pain in the very near future. With the resumption of these studies imminent, we expect that our current cash balance will support multiple potentially catalytic Phase 2 data readouts across our pipeline of innovative CNS product candidates."

    Second Quarter 2020 and Recent Highlights

    • Completed enrollment in Phase 2 exploratory study of NYX-783 in post-traumatic stress disorder (PTSD). In June, Aptinyx announced the completion of enrollment in its Phase 2 exploratory study of NYX-783 in patients with PTSD. In total, 160 patients were enrolled in the study. The company anticipates reporting data from this first-in-patient Phase 2 exploratory study in the fourth quarter of 2020.
    • Hosted virtual R&D Day highlighting the company's development efforts in PTSD. In August, Aptinyx hosted a PTSD-focused R&D Day. The program featured presentations by the Aptinyx management team as well as Murray Stein, MD, MPH, Distinguished Professor of Psychiatry at UCSD and psychiatrist at the VA San Diego Healthcare System.
    • Aptinyx added to the Russell 2000® Index. Effective June 29, 2020, Aptinyx was added as a member of the US small-cap Russell 2000® Index. Russell US Indexes are widely used by investment managers and institutional investors as the basis for index funds and as benchmarks for active investment strategies.

    Expected Upcoming Milestones

    • Recommencement of Phase 2 study of NYX-2925 in patients with fibromyalgia – September 2020.
    • Reporting data from first-in-patient Phase 2 exploratory study of NYX-783 in patients with PTSD – 4Q 2020.
    • Recommencement of Phase 2 study of NYX-2925 in patients with painful diabetic peripheral neuropathy – late 2020/early 2021.

    Second Quarter 2020 Financial Results

    Cash Position: Cash and cash equivalents were $115.9 million at June 30, 2020, compared to $98.8 million at December 31, 2019. Aptinyx expects its current cash balance to support anticipated operations into 2022 and fund multiple Phase 2 data readouts.

    Collaboration Revenue: Revenue was $0.5 million for the second quarter of 2020, compared to $0.9 million for same period in 2019. Aptinyx's revenue was derived from its research collaboration agreement (RCA) with Allergan, now a wholly owned subsidiary of AbbVie. In accordance with the terms of the RCA, jointly funded research activities, and associated payments by Allergan/AbbVie to Aptinyx, are expected to come to their contractual conclusion at the end of August 2020. The company does not rely on these revenues to fund its continuing and expected future operations.

    Research and Development (R&D) Expenses: R&D expenses were $8.4 million for the second quarter of 2020, compared to $9.5 million for the same period in 2019. The decrease in R&D expenses was primarily driven by a decrease in personnel and related support costs.

    General and Administrative (G&A) Expenses: G&A expenses were $4.8 million for the second quarter of 2020, compared to $4.2 million for the same period in 2019. The increase of $0.6 million was primarily due to non-cash stock-based employee compensation expenses.

    Net Loss: Net loss was $12.5 million for the second quarter of 2020, compared to a net loss of $12.1 million for the second quarter of 2019.

    Conference Call

    The Aptinyx management team will host a conference call and webcast today at 5:00 p.m. ET to review its financial results and highlights for the second quarter of 2020 and subsequent period. To access the call, please dial (833) 772-0394 (domestic) or (236) 738-2205 (international) and refer to conference ID 5118404. A live webcast of the call will be available on the Investors & Media section of Aptinyx's website at https://ir.aptinyx.com. The archived webcast will be available approximately two hours after the conference call and for 30 days thereafter.

    About Aptinyx

    Aptinyx Inc. is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of proprietary synthetic small molecules for the treatment of brain and nervous system disorders. Aptinyx has a platform for discovery of novel compounds that work through a unique mechanism to modulate—rather than block or over-activate—NMDA receptors and enhance synaptic plasticity, the foundation of neural cell communication. The company has three product candidates in clinical development in central nervous system indications, including chronic pain, post-traumatic stress disorder, and cognitive impairment associated with Parkinson's disease. Aptinyx is also advancing additional compounds from its proprietary discovery platform, which continues to generate a rich and diverse pipeline of small-molecule NMDA receptor modulators with the potential to treat an array of neurologic disorders. For more information, visit www.aptinyx.com.

    Forward-Looking Statements

    Statements contained in this press release regarding matters that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Such statements include, but are not limited to, statements regarding the company's business plans and objectives, including future plans or expectations for NYX-2925, NYX-783, and NYX-458, therapeutic effects of the company's product candidates and discovery platform, expectations regarding the design, implementation, timing, and success of its current and planned clinical studies, including the timing of recommencement of clinical studies, effects of the COVID-19 pandemic on patient enrollment and the expected timing of study completion, and data reporting, the timing for the company's receipt and announcement of data from its clinical studies, expectations regarding its preclinical development activities, expectations regarding its uses and sufficiency of capital and the effect of the COVID-19 pandemic on the foregoing. Risks that contribute to the uncertain nature of the forward-looking statements include: the effect of the COVID-19 pandemic on our business and financial results, including with respect to disruptions to our clinical studies, business operations, and ability to raise additional capital; the success, cost, and timing of the company's product candidate development activities and planned clinical studies; the company's ability to execute on its strategy; positive results from a clinical study may not necessarily be predictive of the results of future or ongoing clinical studies; regulatory developments in the United States and foreign countries; the company's estimates regarding expenses, future revenue, and capital requirements; the company's ability to fund operations into 2022; as well as those risks and uncertainties set forth in the company's most recent annual report on Form 10-K and subsequent filings with the Securities and Exchange Commission, including our upcoming Quarterly Report on Form 10-Q for the period ended June 30, 2020. All forward-looking statements contained in this press release speak only as of the date on which they were made. Aptinyx undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.

     

    APTINYX INC.

    CONDENSED BALANCE SHEETS

    (in thousands)

    (unaudited)

         

    Assets

     

     

    June 30, 2020

     

     

    December 31, 2019

     

    Current Assets:

     

     

     

     

     

     

     

    Cash and cash equivalents

     

     

    $

    115,878

     

     

    $

    98,849

     

    Restricted cash

     

     

    179

     

     

    179

     

    Accounts receivable

     

     

    490

     

     

    444

     

    Prepaid expenses and other current assets

     

     

    3,688

     

     

    5,637

     

    Total current assets

     

     

    120,235

     

     

    105,109

     

    Property and equipment, net and other long-term assets

     

     

    1,182

     

     

    1,370

     

    Total assets

     

     

    $

    121,417

     

     

    $

    106,479

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

    Liabilities and stockholders' equity

     

     

     

     

     

     

     

    Current Liabilities:

     

    Accounts payable

     

     

    $

    1,532

     

     

    $

    1,555

     

    Accrued expenses and other current liabilities

     

     

    2,384

     

     

    3,341

     

    Total current liabilities

     

     

    3,916

     

     

    4,896

     

    Other long-term liabilities

     

     

    193

     

     

    272

     

    Total liabilities

     

     

    4,109

     

     

    5,168

     

    Stockholders' equity

     

     

    117,308

     

     

    101,311

     

    Total liabilities and stockholders' equity

     

     

    $

    121,417

     

     

    $

    106,479

     

     

    APTINYX INC.

    CONDENSED STATEMENTS OF OPERATIONS

    (in thousands, except per share data)

    (Unaudited)

         

     

     

     

    Three Months Ended

    June 30,

     

     

    Six Months Ended

    June 30,

     

     

     

     

    2020

     

     

    2019

     

     

     

    2020

     

     

    2019

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

    Revenues

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

    Total revenue

     

     

    $

    490

     

     

    $

    925

     

     

     

    $

    1,308

     

     

    $

    1,815

     

     

     

     

     

     

     

     

     

     

     

     

     

     

    Operating expenses

     

     

     

     

     

     

     

     

     

     

     

    Research and development

     

     

    8,365

     

     

    9,481

     

     

     

    19,420

     

     

    21,971

     

     

    General and administrative

     

     

    4,770

     

     

    4,171

     

     

     

    9,669

     

     

    9,896

     

     

    Total operating expenses

     

     

    13,135

     

     

    13,652

     

     

     

    29,089

     

     

    31,867

     

     

     

     

     

     

     

     

     

     

     

     

     

     

    Loss from operations

     

     

    (12,645

    )

     

    (12,727

    )

     

     

    (27,781

    )

     

    (30,052

    )

     

    Other income

     

     

    128

     

     

    596

     

     

     

    554

     

     

    1,210

     

     

    Net loss and comprehensive loss

     

     

    $

    (12,517

    )

     

    $

    (12,131

    )

     

     

    $

    (27,227

    )

     

    $

    (28,842

    )

     

    Net loss per share - basic and diluted

     

     

    $

    (0.27

    )

     

    $

    (0.36

    )

     

     

    $

    (0.61

    )

     

    $

    (0.86

    )

     

    Weighted average shares outstanding - basic and diluted

     

     

    45,680

     

     

    33,493

     

     

     

    44,757

     

     

    33,442

     

     

    Source: Aptinyx Inc.

    View Full Article Hide Full Article
  2. Aptinyx Inc. (NASDAQ:APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today announced that company management will be presenting at the 2020 Wedbush PacGrow Healthcare Virtual Conference. The presentation will take place on Tuesday, August 11, 2020 at 2:20 PM EDT.

    A live webcast of each presentation will be available on the "Events and Presentations" page in the "Investors & Media" section of Aptinyx's website at https://ir.aptinyx.com. A replay of the webcast will be archived on Aptinyx's website for 30 days following the event.

    About Aptinyx

    Aptinyx Inc. is a clinical-stage biopharmaceutical company focused on the discovery, development, and…

    Aptinyx Inc. (NASDAQ:APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today announced that company management will be presenting at the 2020 Wedbush PacGrow Healthcare Virtual Conference. The presentation will take place on Tuesday, August 11, 2020 at 2:20 PM EDT.

    A live webcast of each presentation will be available on the "Events and Presentations" page in the "Investors & Media" section of Aptinyx's website at https://ir.aptinyx.com. A replay of the webcast will be archived on Aptinyx's website for 30 days following the event.

    About Aptinyx

    Aptinyx Inc. is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of proprietary synthetic small molecules for the treatment of brain and nervous system disorders. Aptinyx has a platform for discovery of novel compounds that work through a unique mechanism to modulate—rather than block or over-activate—NMDA receptors and enhance synaptic plasticity, the foundation of neural cell communication. The company has three product candidates in clinical development in central nervous system indications, including chronic pain, post-traumatic stress disorder, and cognitive impairment associated with Parkinson's disease. Aptinyx is also advancing additional compounds from its proprietary discovery platform, which continues to generate a rich and diverse pipeline of small-molecule NMDA receptor modulators with the potential to treat an array of neurologic disorders. For more information, visit www.aptinyx.com.

    Forward-Looking Statements

    Statements contained in this press release regarding matters that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Such statements include, but are not limited to, statements regarding the company's business plans and objectives, including therapeutic effects of the company's product candidates and discovery platform. Risks that contribute to the uncertain nature of the forward-looking statements include: the effect of COVID-19 on our business and financial results, including with respect to disruptions to our clinical trials, business operations, and ability to raise additional capital; the success, cost, and timing of the company's product candidate development activities and planned clinical studies; the company's ability to execute on its strategy; the company's estimates regarding expenses, future revenue, and capital requirements; as well as those risks and uncertainties set forth in the company's most recent annual report on Form 10-k and subsequent filings with the Securities and Exchange Commission. All forward-looking statements contained in this press release speak only as of the date on which they were made. Aptinyx undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.

    Source: Aptinyx Inc.

    View Full Article Hide Full Article
  3. Aptinyx Inc. (NASDAQ:APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today announced that the company will host a conference call and live webcast on Thursday, August 13, 2020 at 5:00 p.m. ET to report second quarter 2020 financial results and discuss recent business highlights.

    To access the live conference call, please dial (833) 772-0394 (domestic) or (236) 738-2205 (international) and refer to conference ID 5118404. A live audio webcast of the event will be available on the Investors & Media section of Aptinyx's website at https://ir.aptinyx.com. A replay of the webcast will be archived on Aptinyx's website for 30 days following the event.

    Aptinyx Inc. (NASDAQ:APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today announced that the company will host a conference call and live webcast on Thursday, August 13, 2020 at 5:00 p.m. ET to report second quarter 2020 financial results and discuss recent business highlights.

    To access the live conference call, please dial (833) 772-0394 (domestic) or (236) 738-2205 (international) and refer to conference ID 5118404. A live audio webcast of the event will be available on the Investors & Media section of Aptinyx's website at https://ir.aptinyx.com. A replay of the webcast will be archived on Aptinyx's website for 30 days following the event.

    About Aptinyx

    Aptinyx Inc. is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of proprietary synthetic small molecules for the treatment of brain and nervous system disorders. Aptinyx has a platform for discovery of novel compounds that work through a unique mechanism to modulate—rather than block or over-activate—NMDA receptors and enhance synaptic plasticity, the foundation of neural cell communication. The company has three product candidates in clinical development in central nervous system indications, including chronic pain, post-traumatic stress disorder, and cognitive impairment associated with Parkinson's disease. Aptinyx is also advancing additional compounds from its proprietary discovery platform, which continues to generate a rich and diverse pipeline of small-molecule NMDA receptor modulators with the potential to treat an array of neurologic disorders. For more information, visit www.aptinyx.com.

    Source: Aptinyx Inc.

    View Full Article Hide Full Article
  4. Program to feature presentation from Dr. Murray Stein, Distinguished Professor of Psychiatry at UCSD and board-certified psychiatrist

    Aptinyx expects data from exploratory Phase 2 study of NYX-783 in PTSD in late 2020

    Aptinyx Inc. (NASDAQ:APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today announced that it will host a virtual R&D Day focused on the company's development efforts in post-traumatic stress disorder (PTSD) on Wednesday, August 5, 2020, from 10:00 a.m. to 11:30 a.m. ET.

    The meeting will feature a presentation from Murray B. Stein MD, MPH, FRCPC. Dr. Stein is Distinguished Professor of Psychiatry and Family Medicine & Public Health…

    Program to feature presentation from Dr. Murray Stein, Distinguished Professor of Psychiatry at UCSD and board-certified psychiatrist

    Aptinyx expects data from exploratory Phase 2 study of NYX-783 in PTSD in late 2020

    Aptinyx Inc. (NASDAQ:APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today announced that it will host a virtual R&D Day focused on the company's development efforts in post-traumatic stress disorder (PTSD) on Wednesday, August 5, 2020, from 10:00 a.m. to 11:30 a.m. ET.

    The meeting will feature a presentation from Murray B. Stein MD, MPH, FRCPC. Dr. Stein is Distinguished Professor of Psychiatry and Family Medicine & Public Health and Vice Chair for Clinical Research in Psychiatry at the University of California San Diego (UCSD). He is also a Staff Psychiatrist at the VA San Diego Healthcare System. Dr. Stein will be available to answer questions following the event.

    The R&D day will also feature presentations by members of Aptinyx's management team, who will provide an overview of the progress of NYX-783, the company's novel NMDA receptor modulator in clinical development for the treatment of PTSD. Last month, Aptinyx announced the completion of enrollment in its ongoing Phase 2 exploratory study of NYX-783 in patients with PTSD. The company anticipates reporting data from the study in late 2020.

    Video Webcast Information

    A live video webcast of the event will be available on the "Events and Presentations" page in the "Investors & Media" section of Aptinyx's website at https://ir.aptinyx.com. A replay of the webcast will be archived on Aptinyx's website following the event.

    About Post-Traumatic Stress Disorder

    Approximately eight and a half million people in the United States suffer from PTSD, which is characterized by intrusive symptoms, avoidance, negative alteration in cognition and mood, hyperarousal, and/or arousal alterations following the experience of trauma. PTSD can result from various forms of trauma, including combat exposure, car accidents, sexual or other physical assault, abuse, natural disasters, and others. The lifetime prevalence of PTSD is approximately seven percent in the general population but is much higher in populations at risk for exposure to trauma, such as military service members and first responders. In addition to the challenges associated with the direct symptoms, PTSD sufferers have a higher rate of suicide and often struggle with simultaneous addiction, leading to an even greater social and economic burden of the disorder. Available therapeutic options are limited, including only two approved conventional SSRI antidepressants, which have limited efficacy, undesirable side effects, and target only the symptoms of PTSD, not the underlying disorder itself.

    About NYX-783

    NYX-783 is a novel, oral NMDA receptor modulator currently in Phase 2 development for the treatment of post-traumatic stress disorder (PTSD). In preclinical studies of NYX-783, particularly strong results were observed in psychiatric models, models of fear extinction, and models of substance abuse. In a Phase 1 clinical study of NYX-783, ample central nervous system exposure was observed and the product candidate demonstrated a favorable safety and tolerability profile, with no serious adverse effects, across a wide dose range. The U.S. Food and Drug Administration has granted Fast Track designation to the development of NYX-783 for the treatment of PTSD.

    About Aptinyx

    Aptinyx Inc. is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of proprietary synthetic small molecules for the treatment of brain and nervous system disorders. Aptinyx has a platform for discovery of novel compounds that work through a unique mechanism to modulate—rather than block or over-activate—NMDA receptors and enhance synaptic plasticity, the foundation of neural cell communication. The company has three product candidates in clinical development in central nervous system indications, including chronic pain, post-traumatic stress disorder, and cognitive impairment associated with Parkinson's disease. Aptinyx is also advancing additional compounds from its proprietary discovery platform, which continues to generate a rich and diverse pipeline of small-molecule NMDA receptor modulators with the potential to treat an array of neurologic disorders. For more information, visit www.aptinyx.com.

    Forward-Looking Statements

    Statements contained in this press release regarding matters that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Such statements include, but are not limited to, statements regarding the company's business plans and objectives, including future plans or expectations for NYX-783 and potential therapeutic effects of NYX-783, expectations regarding the design, implementation, timing, and success of its current and potential clinical studies of NYX-783, the timing for the company's receipt and announcement of data from its exploratory study of NYX-783, and expectations regarding its preclinical development activities. Risks that contribute to the uncertain nature of the forward-looking statements include: the effect of COVID-19 on our business and financial results, including with respect to disruptions to our clinical trials, business operations, and ability to raise additional capital; the success, cost, and timing of the company's product candidate development activities and planned clinical studies; the company's ability to execute on its strategy; that positive results from a clinical study may not necessarily be predictive of the results of future or ongoing clinical studies; regulatory developments in the United States and foreign countries; the company's estimates regarding expenses, future revenue, and capital requirements; as well as those risks and uncertainties set forth in the company's most recent annual report on Form 10-K and subsequent filings with the Securities and Exchange Commission. All forward-looking statements contained in this press release speak only as of the date on which they were made. Aptinyx undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.

    Source: Aptinyx Inc.

    View Full Article Hide Full Article
  5. Aptinyx Inc. (NASDAQ:APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, will be added as a member of the US small-cap Russell 2000® Index. The addition will be effective after the US market opens on June 29, 2020 as part of the 2020 Russell US Indexes annual reconstitution.

    Inclusion in the Russell 2000® Index, which remains in place for one year, is based on membership in the broad-market Russell 3000® Index. Russell US Indexes are widely used by investment managers and institutional investors as the basis for index funds and as benchmarks for active investment strategies. Approximately $9 trillion in assets are benchmarked against Russell US Indexes…

    Aptinyx Inc. (NASDAQ:APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, will be added as a member of the US small-cap Russell 2000® Index. The addition will be effective after the US market opens on June 29, 2020 as part of the 2020 Russell US Indexes annual reconstitution.

    Inclusion in the Russell 2000® Index, which remains in place for one year, is based on membership in the broad-market Russell 3000® Index. Russell US Indexes are widely used by investment managers and institutional investors as the basis for index funds and as benchmarks for active investment strategies. Approximately $9 trillion in assets are benchmarked against Russell US Indexes. Russell US Indexes are part of FTSE Russell's suite of index offerings.

    "We are pleased with the inclusion of Aptinyx in the Russell 2000® Index," said Ashish Khanna, CFO and chief business officer of Aptinyx. "This will enhance the visibility of our company among the investment community and highlight our important efforts to advance the development of our pipeline of novel NMDA receptor modulators for patients suffering from challenging CNS disorders."

    For more information on the Russell 2000® Index and the Russell US Indexes reconstitution, go to the "Russell Reconstitution" section on the FTSE Russell website.

    About Aptinyx

    Aptinyx Inc. is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of proprietary synthetic small molecules for the treatment of brain and nervous system disorders. Aptinyx has a platform for discovery of novel compounds that work through a unique mechanism to modulate—rather than block or over-activate—NMDA receptors and enhance synaptic plasticity, the foundation of neural cell communication. The company has three product candidates in clinical development in central nervous system indications, including chronic pain, post-traumatic stress disorder, and cognitive impairment associated with Parkinson's disease. Aptinyx is also advancing additional compounds from its proprietary discovery platform, which continues to generate a rich and diverse pipeline of small-molecule NMDA receptor modulators with the potential to treat an array of neurologic disorders. For more information, visit www.aptinyx.com.

    About FTSE Russell

    FTSE Russell is a global index leader that provides innovative benchmarking, analytics and data solutions for investors worldwide. FTSE Russell calculates thousands of indexes that measure and benchmark markets and asset classes in more than 70 countries, covering 98% of the investable market globally.

    For more information, visit www.ftserussell.com

    Forward-Looking Statements

    Statements contained in this press release regarding matters that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Such statements include, but are not limited to, statements regarding the company's business plans and objectives, including therapeutic effects of the company's product candidates and discovery platform. Risks that contribute to the uncertain nature of the forward-looking statements include: the effect of COVID-19 on our business and financial results, including with respect to disruptions to our clinical trials, business operations, and ability to raise additional capital; the success, cost, and timing of the company's product candidate development activities and planned clinical studies; the company's ability to execute on its strategy; the company's estimates regarding expenses, future revenue, and capital requirements; as well as those risks and uncertainties set forth in the company's most recent annual report on Form 10-k and subsequent filings with the Securities and Exchange Commission. All forward-looking statements contained in this press release speak only as of the date on which they were made. Aptinyx undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.

    View Full Article Hide Full Article
View All Aptinyx Inc. News